Bristol-Myers Squibb Co (BMS) focuses on the discovery, development, licensing, manufacturing, marketing, selling and distribution of biopharmaceuticals and other healthcare related products. The company’s product portfolio includes chemically synthesized drugs and biologics. It provides products for the treatment of cancer, immunology, cardiovascular, virology, neuroscience and other therapeutic classes. BMS operates in a single segment, BioPharmaceuticals. It discovers, develops and delivers transformational medicines that address serious unmet medical needs.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

The company’s R&D focus on the discovery and development of new molecular entities and expansion of existing products through new indications and formulations. Its pipeline focuses on developing treatments for cancer, immune disorders, cardiovascular and fibrotic diseases. The major pipeline products of the company include opdivo in Phase III for non-small-cell lung carcinoma (NSCLC), opdivo + yervoy in Phase III for treatment of esophageal cancer; onureg and idhifa in Phase III for acute myeloid leukeimia; istodax for peripheral T-cell lymphoma; and breyanzi for diffuse large B-cell lymphoma, among others. The R&D facilities in the US are located at Cambridge in Massachusetts; Summit, New Brunswick, Princeton Pike and Lawrenceville in New Jersey; Redwood City, San Francisco and San Diego in California; and Seattle in Washington. Other R&D facilities are located at Braine-L'Alleud, Belgium; Bangalore, India; Moreton, England; Rueil-Malmaison, France; Seville, Spain; and Tokyo, Japan. The company also owns or leases manufacturing, R&D, administration, storage and distribution facilities at approximately 130 sites worldwide. In FY2023, the company spent US$9,299 million on various R&D activities. Owns several patents in the US and other countries (including EU, Japan and ROW). Collaborates with top tier organizations and research institutes worldwide to develop innovative medicines; and partners with a range of organizations from academia and biotech to global pharmaceutical companies to provide transformative medicines to patients with the highest unmet medical needs. The company has nine R&D centres as of FY2023. Drug platforms include millamolecules, protein homeostasis, small molecules, gene therapy, biologics, cell therapy, epigenetics, antibody-drug conjugates, RNA oligonucleotides and drug delivery technology.